Cargando…
Refractory Methemoglobinemia Secondary to Topical Dapsone With Subsequent Autoimmune Hemolytic Anemia
We present a case of refractory methemoglobinemia with subsequent autoimmune hemolytic anemia in a young female after two days of topical dapsone use. A 15-year-old female with no known genetic risk factors was found to have a methemoglobinemia concentration of 37.1% after presenting with cyanosis,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534637/ https://www.ncbi.nlm.nih.gov/pubmed/36225525 http://dx.doi.org/10.7759/cureus.28811 |
_version_ | 1784802587237679104 |
---|---|
author | Cantrell, Catharine Costers, Vincent Wilson, Chandler C Dudek, Christopher J Arnold, Justin K |
author_facet | Cantrell, Catharine Costers, Vincent Wilson, Chandler C Dudek, Christopher J Arnold, Justin K |
author_sort | Cantrell, Catharine |
collection | PubMed |
description | We present a case of refractory methemoglobinemia with subsequent autoimmune hemolytic anemia in a young female after two days of topical dapsone use. A 15-year-old female with no known genetic risk factors was found to have a methemoglobinemia concentration of 37.1% after presenting with cyanosis, dyspnea, tachycardia, and oxygen saturation of 88% on 15 L of oxygen via a non-rebreather mask. Despite treatment with methylene blue, her methemoglobin concentrations continued to spike, requiring additional doses of methylene blue in addition to ascorbic acid and cimetidine. After discharge on the fourth day, she presented to another hospital with similar symptoms and was again found to have methemoglobinemia before developing autoimmune hemolytic anemia. This patient had no known underlying risk factors, including a normal BMI, normal renal function, two negative glucose-6-phosphate-dehydrogenase (G6PD) deficiency tests, and surprisingly a negative Coombs test. Although rare, particularly in the setting of topical dapsone use, methemoglobinemia remains an important consideration in the differential diagnosis of cyanosis and hypoxia, with early recognition by the emergency medicine physician being imperative for good patient outcomes. |
format | Online Article Text |
id | pubmed-9534637 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-95346372022-10-11 Refractory Methemoglobinemia Secondary to Topical Dapsone With Subsequent Autoimmune Hemolytic Anemia Cantrell, Catharine Costers, Vincent Wilson, Chandler C Dudek, Christopher J Arnold, Justin K Cureus Emergency Medicine We present a case of refractory methemoglobinemia with subsequent autoimmune hemolytic anemia in a young female after two days of topical dapsone use. A 15-year-old female with no known genetic risk factors was found to have a methemoglobinemia concentration of 37.1% after presenting with cyanosis, dyspnea, tachycardia, and oxygen saturation of 88% on 15 L of oxygen via a non-rebreather mask. Despite treatment with methylene blue, her methemoglobin concentrations continued to spike, requiring additional doses of methylene blue in addition to ascorbic acid and cimetidine. After discharge on the fourth day, she presented to another hospital with similar symptoms and was again found to have methemoglobinemia before developing autoimmune hemolytic anemia. This patient had no known underlying risk factors, including a normal BMI, normal renal function, two negative glucose-6-phosphate-dehydrogenase (G6PD) deficiency tests, and surprisingly a negative Coombs test. Although rare, particularly in the setting of topical dapsone use, methemoglobinemia remains an important consideration in the differential diagnosis of cyanosis and hypoxia, with early recognition by the emergency medicine physician being imperative for good patient outcomes. Cureus 2022-09-05 /pmc/articles/PMC9534637/ /pubmed/36225525 http://dx.doi.org/10.7759/cureus.28811 Text en Copyright © 2022, Cantrell et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Emergency Medicine Cantrell, Catharine Costers, Vincent Wilson, Chandler C Dudek, Christopher J Arnold, Justin K Refractory Methemoglobinemia Secondary to Topical Dapsone With Subsequent Autoimmune Hemolytic Anemia |
title | Refractory Methemoglobinemia Secondary to Topical Dapsone With Subsequent Autoimmune Hemolytic Anemia |
title_full | Refractory Methemoglobinemia Secondary to Topical Dapsone With Subsequent Autoimmune Hemolytic Anemia |
title_fullStr | Refractory Methemoglobinemia Secondary to Topical Dapsone With Subsequent Autoimmune Hemolytic Anemia |
title_full_unstemmed | Refractory Methemoglobinemia Secondary to Topical Dapsone With Subsequent Autoimmune Hemolytic Anemia |
title_short | Refractory Methemoglobinemia Secondary to Topical Dapsone With Subsequent Autoimmune Hemolytic Anemia |
title_sort | refractory methemoglobinemia secondary to topical dapsone with subsequent autoimmune hemolytic anemia |
topic | Emergency Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534637/ https://www.ncbi.nlm.nih.gov/pubmed/36225525 http://dx.doi.org/10.7759/cureus.28811 |
work_keys_str_mv | AT cantrellcatharine refractorymethemoglobinemiasecondarytotopicaldapsonewithsubsequentautoimmunehemolyticanemia AT costersvincent refractorymethemoglobinemiasecondarytotopicaldapsonewithsubsequentautoimmunehemolyticanemia AT wilsonchandlerc refractorymethemoglobinemiasecondarytotopicaldapsonewithsubsequentautoimmunehemolyticanemia AT dudekchristopherj refractorymethemoglobinemiasecondarytotopicaldapsonewithsubsequentautoimmunehemolyticanemia AT arnoldjustink refractorymethemoglobinemiasecondarytotopicaldapsonewithsubsequentautoimmunehemolyticanemia |